Crinetics posts positive Phase 2 data for atumelnant; paltusotine NDA on track for 2H 2024

Crinetics Pharmaceuticals, Inc.

Atumelnant: 100% of CAH (n=6) achieved A4 below ULN; 100% of ADCS (n=5) normalized UFC at 80 mg once daily.
Paltusotine: PATHFNDR-2 met primary endpoint – 56% on drug vs 5% placebo achieved IGF-1 ≤1.0xULN (p<0.0001).
PATHFNDR-1 PRO analysis: paltusotine reduced breakthrough symptom exacerbations vs prior injectable SRLs.
Long-term ACROBAT Advance: stable IGF-1, symptom control, and safety at up to 42 months.
Crinetics expects to complete NDA submission for paltusotine in 2H 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.